首页 › 基金 › NEA Management Company, LLC › TRVI

NEA Management Company, LLC 对 TRVI 的持仓历史

TREVI THERAPEUTICS INC · 医疗保健

NEA Management Company, LLC 在 Q3 2026 的 13F 申报中披露持有 TRVI(TREVI THERAPEUTICS INC)13,222,228 股,市值约 US$189.3M,约占其申报组合的 13.88%,在其申报持仓中市值排名第 3 位。 NEA Management Company, LLC 最近 13 个申报季度中有 13 个季度披露了 TRVI 持仓,最早可追溯至 Q3 2023。

最新持仓 (Q3 2026)13.22M 股
申报持仓市值$189.34M
组合权重13.88%
首次申报Q3 2023
最近变动持有
更新于2026-11-17

最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR

NEA Management Company, LLC 对 TRVI 的持仓演变

NEA Management Company, LLC 于 Q3 2023 首次披露 TRVI 持仓:11,370,376 股(约 US$24.8M)。 该持仓在 Q2 2026 达到峰值 13,222,228 股,市值约 US$246.6M。 在 13 次申报中,NEA Management Company, LLC 1 次增持、0 次减持、11 次保持不变。 最近一期申报(Q3 2026)显示持股 13,222,228 股、市值约 US$189.3M。

逐季持仓明细

季度股数金额变化
Q3 2023 11.37M $24.79M 新进
Q4 2023 11.37M $15.24M 持有
Q1 2024 11.37M $39.23M 持有
Q2 2024 11.37M $33.88M 持有
Q3 2024 11.37M $37.98M 持有
Q4 2024 11.37M $48.85M 持有
Q1 2025 11.37M $71.52M 持有
Q2 2025 13.22M $72.33M 增持
Q3 2025 13.22M $120.98M 持有
Q4 2025 13.22M $165.54M 持有
Q1 2026 13.22M $157.74M 持有
Q2 2026 13.22M $246.59M 持有
Q3 2026 13.22M $189.34M 持有

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 TRVI 与 13F 数据

TRVI(TREVI THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 55 只申报持有 TRVI,申报仓位最大的包括:Frazier Life Sciences Management, L.P. (US$136.6M), Vivo Capital, LLC (US$60.6M), MPM BioImpact LLC (US$42.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 TRVI 的基金

查看 TRVI 的全部基金持有人 →

常见问题

How long has NEA Management Company, LLC held TRVI?

NEA Management Company, LLC has disclosed TRVI holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is NEA Management Company, LLC's current position in TRVI?

As of Q3 2026, NEA Management Company, LLC holds 13.22M shares of TRVI (TREVI THERAPEUTICS INC), valued at $189.34M, representing 13.88% of its reported portfolio and ranking #3.

Has NEA Management Company, LLC been buying or selling TRVI?

In the latest 13F filing (Q3 2026), NEA Management Company, LLC held unchanged its position in TRVI. The position peaked in Q2 2026 at 13.22M shares.

Which other funds hold TRVI?

Other major institutional holders of TRVI include Frazier Life Sciences Management, L.P., Vivo Capital, LLC, MPM BioImpact LLC, among 55 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.